SLS — SELLAS Life Sciences Group, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1390478 ·
Last close
$14.32
Market Cap
$2.89B
52W High
$15.88
52W Low
$7.07
ADV30
6,778,325
Next earnings
2026-11-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -9,252,000 | -8,407,000 | 114,177,000 | 107,097,000 | 6,765,000 |
| Dec 2025 | 0 | — | -8,255,000 | -7,658,000 | 78,345,000 | 71,793,000 | 7,474,000 |
| Sep 2025 | 0 | — | -7,083,000 | -6,791,000 | 51,555,000 | 44,320,000 | 5,925,000 |
| Jun 2025 | 0 | — | -6,873,000 | -6,601,000 | 32,305,000 | 25,297,000 | 6,156,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-28,165,000
Investing CF
$0
Financing CF
$106,865,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.25
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-283,395,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-31,463,000
Pretax Income TTM
$-29,457,000
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -28,274,000 | -26,863,000 | 78,345,000 | 7,474,000 | — | -28,389,000 |
| Dec 2024 | 0 | -31,513,000 | -30,881,000 | 19,432,000 | 9,967,000 | — | -35,402,000 |
| Dec 2023 | 0 | -37,869,000 | -37,340,000 | 6,219,000 | 14,195,000 | — | -31,410,000 |
| Dec 2022 | 1,000,000 | -31,950,000 | -41,301,000 | 20,943,000 | 16,092,000 | — | -23,809,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$16,690,000
NetIncome TTM
$-30,482,000
OpCashFlow TTM
$0
Assets (Latest)
$19,432,000
Forward EPS
$-0.10
Max Pain — expiry 2026-08-28
max pain strike: $14.00 · spot: $14.33 · call oi: 20,932 · put oi: 7,449
Expected Move to 2026-08-28:
±$1.75
(12.21%) —
implied range
$12.58 –
$16.08
· ATM straddle on $14.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ZLAB | Zai Lab Ltd | $2.88B | $25.64 | — |
| ALMS | ALUMIS INC. | $2.98B | $23.03 | — |
| ATAI | AtaiBeckley Inc. | $2.74B | $7.38 | — |
| NRIX | Nurix Therapeutics, Inc. | $2.73B | $26.27 | — |
| VRDN | Viridian Therapeutics, Inc.\DE | $2.72B | $24.02 | — |
News headlines (Yahoo Finance, 1h cache)
SLS Traders Eye This Important Resistance Zone Ahead Of Key AML Data Readout
2026-08-24 16:12 · Yahoo
SLS Stock Charges Ahead As AML Trial Buzz Builds: Report Claims Regal Hit 80th Event — Retail Isn’t Convinced
2026-08-24 03:36 · Yahoo
SLS Stock Clocks Three Straight Weeks Of Gains On Cancer Vaccine Spillover, REGAL Trial Data Anticipation
2026-08-21 21:19 · Yahoo
Is SELLAS (SLS) Turning Sector Hype Into a Durable Cancer Vaccine Story Despite Ongoing Losses?
2026-08-21 06:10 · Yahoo
SELLAS Life Sciences Group (SLS) Stock Looks Stretched Despite Key AML Trial Progress
2026-08-21 04:30 · Yahoo
SLS, IBRX Stocks In Focus: Analyst Says Moderna-Merck Cancer Vaccine Success ‘Bodes Well’ For Oncology
2026-08-21 02:46 · Yahoo
SLS Stock Edges Higher As Wall Street, Retail Expect Another MRNA Moment
2026-08-19 19:38 · Yahoo
Sellas CEO Angelos Stergiou Highlights Pediatric Leukemia Study That ‘Directly Supports’ Scientific Basis Of Regal Trial
2026-08-17 17:09 · Yahoo
Sellas’ Experimental Drug SLS009 Appears To Be Leading The CDK9 Race, Says Alliance Global – Analyst Sees About 200% Upside Potential
2026-08-12 16:07 · Yahoo
SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-11 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.